NCI-H69/LX4

96042329

• UNSPSC-Code: 41106514

Eigenschaften

• Biologische Quelle: human lung
• Wachstumsmodus: Aggregates in suspension
• Karyotyp: Not specified
• Morphologie: Not specified
• Produkte: Not specified
• Rezeptoren: Not specified
• Methode(n): cell culture | mammalian: suitable
• Relevante Krankheit(en): cancer
• Versandbedingung: dry ice
• Lagertemp.: −196°C

Beschreibung

Ursprung der Zelllinie

Human Caucasian small cell lung carcinoma, drug-resistant

Beschreibung der Zelllinie

NCI-H69/LX4 has been established by exposure of the parent line, H69 (Sigma Catalogue number. 91091802) to doxorubicin, also known as adriamycin. The line hyperexpresses P-glycoprotein and demonstrates a multidrug resistant drug accumulation deficit. It is recommended to culture the cells without drug after resuscitation until the first passage.

Anwendung

Analysis of acquired drug-resistance, study of small cell lung cancer

DNA-Profil

STR-PCR Data: Amelogenin: X,Y
CSF1PO: 10,12
D13S317: 12
D16S539: 11
D5S818: 11,13
D7S820: 9
THO1: 8,9
TPOX: 10
vWA: 16,17

Nährmedium

RPMI + 2mM Glutamine + 0.4μg/ml doxorubicine + 10% Foetal Bovine Serum (FBS).

Subkultur-Routine

Split sub-confluent cultures (70-80%) by repeated pipetting of aggregates or scraping; 5% CO₂; 37°C

Sonstige Hinweise

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.